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[57] ABSTRACT
The invention relates to a process for preparing substi-
tuted po1ycyc1o-alkylidene polycyclo-alkanes, such as
substituted adamanty1idene adamantanes, and the corre-
sponding epidioxy compounds, in which polycyclo-
alkylidene polycyclo-alkanes are halogenated with an N-
halosuccinimide, tert.-butylhypohalite or sodium
hypohalite/CH3COOH, the halogenation product is
optionally subjected to a substitution reaction, and the
substituted polycycloalkylidene polycyclo-alkanes are
converted to the corresponding epidioxy compounds in a
way known per se.
Further, the invention relates to compounds of formula
44
in which A and B represent alkylene radicals, which
alkylene radicals may be attached to each other via an
alkylene radical C, and R1 represents a substituent,
which, in case of 4-eq.-R1-2,2'-adamantylidene adaman-
tane cannot be chloro, hydroxy, oxo, D or a group of
formula 1:
as well as to compounds of formula 45:
(Abstract continued on next page.)
4,705,847
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in which A, Band C are as defined above, and R2 is a
substituent which, in case of 4-eq.-R2-2,2' epidioxy-2,2'-
adamantyl adamantane cannot be chloro or hydroxy.
Compounds of formula 45 are useful as thermochemilu-
minescent labels and probes in the study of biological
processes and in immuno-assays.
34 Claims, 47 Drawing Figures
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KANES, EPIDIOXY DERIVATIVES THEREOF
AND METHOD OF PREPARATION
BACKGROUND OF THE INVENTION
A process for preparing substituted polycyclo-
alkylidene polycyclo-alkanes and the corresponding
epidioxy compounds; as well as said substituted
polycyclo-alkylidene polycyclo-alkanes and the
corresponding epidioxy compounds.
The invention relates to a process for preparing sub-
stituted polycyclo-alkylidene polycyclo-alkanes and
the corresponding epidioxy compounds, as well as to
these substituted polycycloalkylidene polycyclo-
alkanes and the corresponding epidioxy compounds.
The term "substituted polycyclo-alkylidene polycy-
clo-alkanes" as used herein comprises especially com-
pounds of formula 44 of the formula sheet, in which A
and B represent alkylene radicals, which alkylene radi-
cals may be attached to each other via an alkylene radi-
cal C, and wherein R1 represents a substituent which,
in the case of 4-equatorially R1-Substituted 2.2'-
adamantylidene adamantanes, cannot be chloro,
hydroxy, oxo, D or a radical of formula 1 of the
formula sheet. In preferred compounds of formula 44,
alkylene radical A contains 2 to 5 carbo atoms,
alkylene radical B 2 to 5 carbon atoms, and alkylene
radical C, if present, 1 to 4 carbon atoms. Examples of
compounds of formula 44 are 4-eq-R1-2,2'
adamantylidene adamantanes, 4-eq-R19,9'-bicyclo
[3,3,1]-nonylidene-bicyclo[3,3,1]-nonanes, 2- or 7-R1-
8,8'-bicyclo[3,2,1]-octylidene-bicyclo[3,2,1]ctanes
and 2- or 7-R1-10,10'-bicyclo[4,3,1]-decylidene-
bicyclo[4,3,1]-decanes, in which the two rings of each
of the bicyclic radicals may be attached to each other
via an alkylene bridge.
The corresponding epidioxy compounds-which
contain a dioxetane ring-are especially compounds of
formula 45, in which A, Band C, if present, have the
above-mentioned meanings, and R2 represents a substi-
tuent which, in the case of 4-eq-R2-2,2'-epidioxy-2,2'-
adamantyl adamantane cannot be chloro or hydroxy.
The invention relates to these compounds and to
processes for the preparation thereof. Especially, the
invention relates to a process for preparing substituted
polycyclo-alkylidene polycyclo-alkanes, in which a
corresponding non-substituted compound is subjected
to a halogenation reaction, using a halogenating agent
in a solvent, and the halogenation product is recovered
from the reaction mixture and/or, if desired, is sub-
jected to a substitution reaction.
In Tetrahedron Letters 1970, 4579-82, J. H. Wie-
ringa, J. Strating and H. Wynberg describe a process in
which adamantylidene adamantane is reacted with
chlorine is tetrachloromethane at a temperature of -20°
to +10° C. to form 4-eq.-chloroadamantylidene
adamantane in addition to polychlorinated products.
The chloro-substituted adamantane compound is the
starting point for further reaction in the presence of
AgNO3 and THF/H2O to form a mixture of the corre-
sponding 4-hydroxy-adamantylidene adamantane com-
pounds, which with the appropriate oxidant (Jones
reagent: CrO3, H2SO4, acetone) are finally converted
into the corresponding ketone compound, in which the
carbonyl group is in the 4-position.
SUMMARY OF THE INVENTION
It is an object of the invention to provide a process
for preparing substituted polycyclo-alkylidene polycy-
clo-alkane compounds, in which these compounds are
selectively produced in a high yield and in a simple
manner and/or from which other substituted polycyclo-
alkylidene polycyclo-alkane compounds can be
selectively prepared in a high yield.
According to the invention, for this purpose, the
process as defined above is carried out using as the
halogenating agent N-halosuccinimide, tert-butyl-
hypohalite, or sodium hypohalite/CH3COO .
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 illustrates a dioxazole radical which can be a
substituent in some of the compounds of this invention.
FIG. 2 illustrates the structural formula of 4-eq.
chloroadamantylideneadamantane.
FIG. 3 illustrates the structural formula of 4-eq.-
hydroxyadamantylideneadamantane.
FIG. 4a illustrates the structural formula of a 4-eq.-4'-
eq.-bisadamantylidene adamantyl ether when R is the
radical of FIG. 4b.
FIG. 4b illustrates the structural formula of a 4-eq-
adamantylideneadamantyl radical.
FIG. 5 illustrates the structural formula of 4-eq.-
methoxyadamantylideneadamantane .
FIG. 6 illustrates the structural formula of 4-eq.-n-
octyloxyadamantylideneadamantane.
FIG. 7 illustrates the structural formula of O-(4-eq.-
adamantylideneadamandyl)lactamide .
FIG. 8 illustrates the structural formula of N-(4-eq.-
adamantylideneadamantyl)acetamide.
FIG. 9 illustrates the structural formula of N-(4-eq.-
adamantylideneadamantyl)-3-hydroxypropionamide.
FIG. 10 illustrates the structural formula of N-(4-eq.-
admantylideneadamanty1)lactamide.
FIG. 11 illustrates the structural formula of N-(4-eq.-
adamantylidene adamantyl)acrylamide.
FIG. 12 illustrates the structural formula of adaman-
tylideneadamantan-4-one.
FIG. 13 illustrates the structural formula of N-(4-eq.-
adamantylideneadamantyl)ethyl carbamate.
FIG. 14 illustrates the structural formula of 4-eq.-
adamantylideneadamantane isothiocyanate.
FIG. 15 illustrates the structural formula of adaman-
tylideneadamantane.
FIG. 16 illustrates the structural formula of 4-eq.-
bromoadamantylideneadamantane.
FIG. 17 illustrates the structural formula of bicy-
clo[3.3.1]-nonylidene-bicyclo[3.3.1]nonane.
FIG. 18 illustrates the structural formula of 4-eq.-
chlorobicyclo[3.3.1]nonylidene-bicyclo[3.3.1]nonane.
FIG. 19 illustrates the structural formula of 4-eq.-(2-
chloroethoxy)adamantylideneadamantane.
FIG. 20 illustrates the structural formula of 4-eq.-(3-
bromopropyloxy)adamantylideneadamantane.
FIG. 21 illustrates the structural formula of 4-eq.-(L)-
menthoxyadamantylideneadamantane.
FIG. 22 illustrates the structural formula of 17-beta[4-
eq.-adamantylideneadamantyloxy]testosterone.
FIG. 23 illustrates the structural formula of 4-eq.-(iso-
propyloxy)adamantylideneadamantane.
FIG. 24 illustrates the structural formula of 4-eq.-(3-
hydroxypropyloxy)adamantylideneadamantane.

















FIG. 26 illustrates the structural formula of N-(4-eq.-
adamantylidene adamanty1)-3-hydroxypropionamide.
FIG. 27 illustrates the structural formula of 4-eq.-
iodoadamantylideneadamantane.
FIG. 29 illustrates 4-eq.-(alpha-iodoacetoxy)-2,2'-epi-
dioxy-2,2'-adamantyladamantane (anti-isomer) of the
invention.
FIG. 31 illustrates 3-O-(4-eq.-2,2'-epidioxy-2,2'-
adamantyladamantane)lithocholic acid of the invention.
FIG. 32 illustrates the structural formula of 4-eq.-[12-
oxydodecanoic acid methyl ester(adamantylideneada-
mantane.
FIG. 33 illustrates the structural formula of 4-eq.-(12-
oxydodecanoic acid methyl ester]adamantylideneada-
mantane-1,2-dioxetane.
FIG. 34 illustrates the structural formula of 4-eq.-(12-
oxydodecanoic acid]adamantylideneadamantane-l,2-
dioxetane.
FIG. 35 illustrates the structural formula of 12-hydr-
doxydodecanoic acid methyl ester.
FIG. 36 illustrates the structural formula of dodecane
lactone.
FIG. 37 illustrates the structural formula of lithocholic
acid methyl ester.
FIG. 38 illustrates the structural formula of 3-O-(4-
eq.-adamantylideneadamantyl)lithocholic acid methyl
ester.
FIG. 39 illustrates the structural formula of 3-O-(4eq.-
2,2'-epidioxy 2,2'-adamantyladamantane)lithocholic
acid methyl ester.
FIG. 40 illustrates the structural formula of N-(4-eq.-
adamantylideneadamantyl)maleimide.
FIG. 41 illustrates the structural formula of silver
maleimide.
FIG. 42a illustrates the structural formula of an iso-
mer of 4-eq.-(maleimido)-2,2'-epidioxy-2,2'-adamantyl-
adamantane.
FIG. 42b illustrates the structural formula of an iso-
mer of 4-eq.-(maleimido)-2,2'-epidioxy-2,2'-adamantyl-
adamantane.
FIG. 43 illustrates the structural formula of 4-eq.-
hydroxy-2,2'-epidioxyadamantylideneadamantane.
FIG. 44 illustrates the structural formula of the sub-
stituted adamantylideneadamantane compounds of the
invention.
FIG. 45 illustrates the structural formula of the 2,2'-
epidioxy derivatives of the substituted adaman-
tylideneadamantane compounds of the invention.
The invention is based on the surprising discovery
that, with the halogenating agents mentioned, polycy-
clo-alkylidene polycyclo-alkanes which can be consid-
ered to be tetra-alkyl ethylene compounds, such as the
adamantylidene adamantane, produce halogenation
products with a structure, namely, the 4-eq.-halogen-
substituted structure, which differs from the structure
normally to be expected in reactions of these halogenat-
ing agents with mono-, di- and trialkylethylene com-
pounds. Thus, in the process according to the invention,
halogenation of the adamantylidene adamantane by
means of N-chlorosuccinimide in boiling CCl4 and in
the presence of a radical initiator exclusively produces
the 4-eq.-chloro-substituted compound. This halogena-
tion reaction, carried out in CH2Cl2 at room temperatu e
and in the absence of a radical initiator, produces the 4-
eq.-chloro-substituted compound in a quantitative yield
in a smoothly proceeding reaction. The halogenation
reaction also takes place in CCl4, CHCl3, or in a
mixture of CH2Cl2/CH3COOH, with the reaction velo-
city increasing with increasing polarity of the solvent.
It has been found that, in the presence of a radical
inhibitor, for example hydroquinone, the halogenation
r action takes place at a high rate.
A further elaboration of the process according to the
invention concerns causing the chlorine atom in the
chloro-substituted compound formed to participate in a
substitution reaction in a solvent in the presence of a
silver salt, using as the substituting agent, in addition
to the silver salt, a nucleophile, for example, an
alcohol, a cyanide, a carbamate, or an isothiocyanate.
When, for example, 4-eq.-chloroadamantylidene ada-
mant ne is dissolved in an alcohol or a mixture of the
alcohol and dioxane and AgBF4 is added, a fast pro-
ceeding reaction takes place, in which the correspond-
ing ether is formed without appreciable quantities of
byproduct. In this reaction, the reaction components
may be directly mixed with each other, whereby they
react at room temperature or at a slightly elevated tem-
perature. The degree of selectivity of the formation of
a given ether is promoted by a careful preparation of
the reaction components in the sense that they should
be thoroughly dry .
In the reaction of 4-eq.-chloroadamantylidene ada-
mantane with certain alcohols, for example, methanol,
n-octanol-1 and hydroxy-acetone, these alcohols may
themselves serve as the solvent, and hence be used in
large excess. It has been found, however, that the yield
of product ether did not decrease dramatically when a
lower concentration of the alcohol component in the
reaction mixture is selected.
When 4-eq.-chloroadamantylidene admantane is re-
acted with a nitrile as the nucleophile in the presence
of AgBF4, taking care that the imminium ions formed
are hydrolysed with water, there is produced N-(4-eq.-
adamantylidene adamantyl)amide, albeit that, general-
ly speaking, these reactions with a nitrile proceed at a
lower rate than with alcohols while the yield is also
comparatively lower .
The reaction of, in particular, 4-eq.-chloroadaman-
tylidene adamantane with alcohols to form ethers and
with nitriles to form amides are the first steps on a
route leading to diverse 4-eq.-substituted adamantyli-
dene adamantanes, and via these compounds to the
corresponding 1,2-dioxetanes, which will be entered
into later.
In a preferred embodiment of the process according
to the invention, the halogenating agent is a brominat-
ing agent, for example, N-bromosuccinimide, and, in
accordance with the above, there is then produced the
4-eq.-bromo-substituted compound. When the starting
point is, for example, the adamantylidene adamantane,
heating for 12 hours at 40° C. produces 4-eq.-
bromoadamantylidene adamantane according to a fully
completed reaction.
The 4-eq.-bromoadamantylidene adamantane has bee
found to have particularly advantageous and unex-
pected properties. Thus, unlike the corresponding 4-
eq.-chloroadamantylidene adamantane, this compound
permits carrying out substitution reactions by means of
solvolysis without requiring an adjuvant such as an
Ag+ salt. It has moreover been found that certain sub-
stituents can be introduced in one step where this had
not been possible before. The 4-eq.-bromoadamantyli-
den  adamantane reacts with primary and secondary
alcohols to form ethers, with carboxylic acids to form
















and with nitriles to form N-adamantylidene adamantyl
amides. Furthermore it has been found to be possible
to carry out halogen exchange reactions with this com-
pound, for example, in a reaction with NaI/acetone.
Reaction of 4-eq.-bromoadamantylidene adamantane
with H2O/dioxane gives a quantitative yield of 4-eq.-
hydroxyadamantylidene adamantane. The solvolysis
reactions are carried out in the pure reagent as the sol-
vent or together with dioxane or DMF as a co-solvent.
According to another elaboration of the process ac-
cording to the invention, the symmetrical polycyclo-
alkylidene polycycloalkane used as the starting point is
adamantylidene adamantane. Preferably the 4-eq.-sub-
stituted adamantylidene adamantane is subjected to a
photo-oxigenation reaction to form the 4-eq.-substitu-
ted 1,2-dioxetane, as 1,2-dioxetanes have particularly
advantageous properties, as will be explained in more
detail hereinafter .
DETAILED DESCRIPTION OF THE
INVENTION AND PREFERRED
EMBODIMENTS
The invention also relates to substituted polycy-
cloalkylidene polycycloalkanes, especially to com-
pounds of formula 44 as defined above, and preferably
to 4-eq.-R1-substituted adamantylidene adamantane
compounds, and in particular those in which R1 is bro-
mine, with the exception of the known per se 4-eq.-R1-
substitutedadamantylidene adamantanes in which R is
chlorine, hydroxyl, oxo, D or a group having the for-
mula 1 of the sheet of formulae. A favourable property
of adamantylidene adamantanes in general is that the
1,2-dioxetanes produced from them exhibit a good sta-
bility, as appears from a summary of a so-called "pos-
ter session" on bio- and chemiluminescence, published
in June 1981 by Academic Press, New York.
1,2-dioxetanes themselves are stated in an article by
T. Wilson in Int. Rev. Sci.: Phys. Chem. Ser. Two 9
(1976) 265 to be suitable as thermochemiluminescent
compounds, with the possibility of controlling the che-
miluminescence emitted by regulating the temperature
of the system.
In accordance with the above, the invention accord-
ingly also relates to chemiluminescent compounds of
formula 45, in which A and B represent alkylene radi-
cals, which alkylene radicals may be attached to each
other via an alkylene radical C, and wherein R2 r pre-
sents a substituent which, in the case of 4-eq.-R2-2,2'-
epidioxy-2,2'-adamantyl adamantane cannot be chloro
or hydroxy.
In preferred compounds of formula 45 the alkylene
radical A contains 2 to 5 carbon atoms, the alkylene
radical B 2 to 5 carbon atoms, and the alkylene radical
C, if present, 1 to 4 carbon atoms. In particular, the
invention relates to 4-eq.-R2-2,2'-epidioxy-2,2'-ada-
mantyl adamantanes in which R2 represents a substitu-
ent, with the exception of chloro or hydroxy.
For example, the substituent R2 may be chloro,
bromo or iodo, a hydroxy group, an optionally substi-
tuted alkoxy, cycloalkoxy or acyloxy group, or an
amino, acylamino, isothiocyanato or isocyanato group,
with the proviso that in case of 4-eq.-R2-2,2'-epidioxy-
2,2'-adamantyl adamantanes R2 cannot be chloro or
hydroxy.
In particular, the substituent R2 represents a radical
of a biologically active compound, such as of a fatty
acid, a steroid, or a protein. In that case the compound
of formula 45 is a biologically active substance labelled
with a chemiluminescent 1,2-dioxetane.
It is true that is known, within the framework of the
analytical techniques used in biochemistry, clinical
chemistry and biology for the qualitative and quantita-
tive analysis and structural assay of biological materials
t  use luminescent labels and probes. The compounds
have chemiluminescent properties, such as luminol and
other phthalohydrazide derivatives used in these tech-
niques, however, have the limitation that their chemilu-
minescence can only be generated by adding oxidants,
for example hydrogen peroxide.
The novel chemiluminescent labels according to the
present invention are suitable for use in immunochemi-
cal methods of determination, in particular immunoas-
say, and the study of steroids and membranes. Unlike
known agents, such as luminol, the chemiluminescence
is generated solely by heating.
To study, in particular, membranes, the thermo-
chemiluminescent compounds according to the inven-
tion are modified to a label which exhibits chemilumi-
nescence at a temperature of at least 150° C. and up to
approximately 250° C. By suitable substitution of the
1,2-dioxetane according to the invention, for example,
by a long-chain fatty acid, the label is rendered
compatible with the surroundings to be studied at the
membrane.
A thermochemiluminescent fatty acid compound
according to the invention is, for example, the com-
pound of formula 28, in which the fatty acid radical is
derived from arachidic acid. Such a compound has been
found to have properties analogous to those of long-
chain fatty acids, and to be suitable for use as a
chemiluminescent label in membrane studies.
For chemiluminescence immunoassay based on a
specific antibody-antigen reaction, a dioxetane com-
pound according to the invention is modified to a "la-
bel", for example a protein label which is specific rela-
tive to certain functional groups in peptides.
Thus, for example, a protein may be marked at a free
thiol group with a 4-eq.-substituted 2,2'-epidioxy-2,2'-
adamantyl adamantane in which the substituent is a-
iodoacetoxy of maleimido (formulae 29 and 42, respec-
tively, of the sheet of formulae). The 1,2-dioxetane thus
substituted may be reacted under standard conditions
with, for example, Bovine Serum Albumine, which is a
protein having 0.7 mole of free thio groups per mole of
protein. Purification of the reaction product by chroma-
tography over a Sephadex G-10 column, dialysis against
distilled water, and freeze drying produces the chemilu-
minescent protein. This procedure may also be applied
to other proteins and, for example, to glutathione.
For immunoassay on the basis of chemiluminescence
for steroid investigation, the 1,2-dioxetane compound
ccording to the invention may be attached to, for ex-
ample, lithocholic acid ( formula 31) or testosterone
(formula 22).
The invention is illustrated in and by the following
examples.
EXAMPLE I
In the examples, melting points were determined by
means of a Mettler FP2 melting point apparatus. IR
spectra were recorded with a Unicam (SP-200) spectro-
photometer and 1H NMR spectra with a Varian A-60 of
Hitachi Perkin Elmer R-24 B at 60 Mc. 1H chemical

















13CMR spectra were recorded at 25 Mc (Varian XL-
100) and 13C chemical shifts are indicated in d units
(ppm) relative to the solvent CDCl3 and converted to d
TMS values using dD KCl3 = 76.9 ppm.
Mass spectra were recorded by means of a Perkin
Elmer Polarimeter using a 10 cm cell.
All solvents were purified and dried according to
standard conditions. Silvers salts (AgBF4; AgClO4)
were dried with P2O5 at 0.001 mm Hg for 10-20 hours.
The 4-eq.-chloroadamantylidene adamantane (for-
mula 2 of the sheet of formulae) used in the examples
can be characterized as follows: melting point 142°-
143° C. 13C NMR (CDCl3): 137.0; 130.8; 68.3; 39.4;
39.2; 38.8; 37.0; 35.6; 32.4; 32.1; 30.4; 30.4; 28.3;
27.6.
Preparation of 4-eq.-hydroxyadamantylidene
adamantane (formula 3) and 4-eq.-,
4'-eq.-bisadamantylidene adamantyl ether (formula 4a
in which R represents a group having formula 4b)
4-eq.-chloroadamentylidene adamantane having for-
mula 2 (12.8 g; 40 mmoles) was dissolved in dioxane
(160 cm3) and distilled water (40 cm3) was added. The
mixtures was refluxed, and with stirring, AgBF4 (10 g,
50 mmoles) was added in small quantities together with
120 cm3 dioxane over a period of 75 minutes.
Refluxing was continued for 15 minutes, whereafter the
reaction mixture was cooled, filtered and concentrated.
The residue was taken up in ether (120 cm3), the
ethereal solution was washed with water (3 ´ 100 cm3),
dried with MgSO4, decolourized with 1 g activated
charcoal, filtered and evaporated to yield 11.09 (97%)
of the compound having formula 3 in the form of a
white powder having a melting point of 211.5°-213° C.
When the reaction was carried out in a dioxane/water
(25/1) mixture and AgBF4 was added all at once, after
work-up and chromatography over Al2O3 (act. II/III)
using CH2Cl2 as the eluent, the compound having
formula 4a, in which R represents the group having
formula 4b, cound be isolated in a yield of 25%. Even
after recrystallization (from n-hexane) a sharp melting
point could not be obtained, probably because the com-
pound having formula 4a consisted of a mixture of dia-
stereo-isomers. 1H NMR (CDCl3) d 3.33 (br, 2H); 3.05-
2.55 (m, 8H); 2.50-1.1 (m, 44H). 13C NMR (CDl3): d
135.2; 135.1; 131.6; 131.4; 80.7; 39.7; 39.5; 39.2; 37.2;
33.4; 32.3; 32.1; 31.4; 31.0; 28.5; 21.8: IR (KBr) 2900
(s), 1455 (m), 1080 (s), 1035 (m) and 975 (m) cm-1.
Mass: M+ at m/e 550 (30%), 267 (100%) with
metastable peak at 129.6. Exact mass: calculated for




The chloro-substituted compound having formula 2
(605 mg, 2 mmoles) was suspended in very dry MeOH
(10 cm3) under a nitrogen atmosphere and using a mag-
netic stirrer. Subsequently 600 mg (3 mmoles) AgBF4
was added and the mixture was refluxed for 30 min.
AgCl was fIltered off and Et2O (50 cm3) was added.
The solution was washed with H2O (2 ´  100 cm
3),
dried with MgSO4, filtered and concentrated at a re-
duced pressure to produce 520 mg (88%) spectroscopi-
cally pure compound having formula 5 in the form of a
colourless oil. "Kugelrohr" distillation (170°-180° /0.1
mm Hg) yielded 500 mg analytically pure material
which solidified on standing: 1H NMR (CDCl3): d 3.3
(br, 1H); d 3.3-2.6 (br-5H); d 2.3-2.1 (br, 22H). 13C
NMR (CDCl3): 135.3, 130.8; 83.3; 54.9; 39.3; 39.0;
37.0; 36.7; 35.1; 32.6; 32.2; 31.8; 31.0; 30.8; 28.3;
24.5. Mass: M+ at m/e 298 (100). IR (neat) 2900, 1450
and 1095 cm-1. Analysis: calculated for C21H30O:




The chloro-substituted compound having formula 2
(605 mg, 2 mmoles) was suspended in n-octanol-1 (5
cm3). With stirring by means of a magnetic stirrer,
AgBF4 (600 mg, 3 mmoles) was added in 2 portions.
The mixture was heated for 5 minutes at 100° C. and
then allowed to cool to room temperature while it was
stirred for 3 hours. Ether (75 cm3) was added and the
solution was washed with water (2 ´ 100 cm3), dried
with MgSO4, filtered and evaporated at 0.3 mm/100°
C. Column chromatography over Al2O3 (act. II/III)
using CH2Cl2 as the eluent produced 640 mg (81% )
spectroscopically pure compound having formula 6 in
the form of a colourless oil. 1H-NMR (CDCl3) d 3.55-
3.10 (3H, m); d 3.10-2.60 (4H, m); d 2.33-0.6 (37H). -
C NMR (CDCl3): d 135.1; 131.2; 81.6; 67.3; 39.4;
39.1; 37.1; 36.8; 35.6; 32.9; 32.3; 31.9; 31.7; 31.0;
30.2; 29.4; 29.1; 28.4; 27.6; 26.2; 22.5; 13.8. Mass:
M+ at m/e 396, 267, 266, 41 (100%). Exact mass:




To a solution of 2.0 g l-lactamide (Merck) and 605
mg (2 mmoles) of chloro-substituted compound having
formula 2 in 15 cm3 dioxane, AgBF4 (4 mmoles) was
added with vigorous stirring at 70° C. The mixture was
stirred at room temperature for 20 hours, diluted with
ether (150 cm3), washed with water, dried with
MgSO4, filtered and concentrated to produce 600 mg
of a white material. Column chromatography using Al-
2O3/CH2Cl2 gave 200 mg non-reacted compound hav-
ing formula 2 and then 330 mg of the compound
having formula 7 (70%, based on converted compound
having formula 2), which solidified when stripped with
ether; melting point 133°-135° C. 1H-NMR (CDCl3)
6.4 (br, 2H); 3.88 (q, J=6.5 c.; 1H); d 3.32 (m, 1H); d
2.80 (m, 4H); 2.3-1.1 (m, 25H) with doublet at 1.39,
J=6.5 Hz. 13C-NMR (CDCl3): d 177.4; 135.9; 130.0;
81.1; 80.8; 73.1 (br); 39.2; 38.6; 36.8; 36.5; 35.8; 32.8;
32.1; 31.8; 30.9; 30.5; 28.1; 27.2; 18.8; 18.5. IR (KBr):
3460, 3300, 2900, 1670, 1580, 1450, 1100, 1060 cm-1.
Mass: m+ at m/e 355, 267, 131, 91. Exact mass:




A solution of 1.21 (4 mmoles) of the compound hav-
ing formula 2 in 20 cm3 dry dioxane was added to a
stirred solution of 1.2 g AgBF4 in 20 cm
3 CH3CN and
20 cm3 dioxane in a period of 5 minutes and at reflux
temperature. After completion of the addition, the
whole was stirred for 1 hour and a half without further
heating. Water (2 cm3) was added and after stirring for
















pressure. To the residue, 300 cm3 ether was added and
after filtration over a glass filter, the ethereal solution
was washed with water (3 ´ 300 cm3), dried with
MgSO4, filtered and concentrated to produce 1.11 g of
the crude compound having formula 8 in the form of a
white foam. Column chromatography over Cl2O3, using
first hexane (150 cm3) and then CH2Cl2 as eluents
produced 0.86 g (66%) pure acetamide in the form of
white crystals; melting point 159°-161° C. (from hex-
ane). 1H-NMR (CDCl3): d 5.75 (br, 1H); 3.9 (br, 1H);
2.88 (m, 4H); 2.4-1.3 (m, 25H, with peak for -CH3 at
2.00). 13C-NMR (CDCl3): d 169.0; 135.8; 130.5; 53.9;
39.3; 39.0; 38.8; 37.6; 37.1; 35.3; 33.2; 32.0; 31.7; 31.3;
30.6; 28.3; 28.2; 27.3; 23.5. IR (KBr) 3400, 2950, 1650,
1550, 1460 and 1090 cm-1. Mass: M+ at m/e 325, 213,





The chloro-substituted compound having formula 2
(605 mg, 2 mmoles), 3-hydroxypropionitrile (10 cm3)
and dioxane (50 cm3) were mixed together under a
nitrogen atmosphere at 70° C. to produce a homogene-
ous solution. AgBF4 (600 mg, 3 mmoles) was added and
the mixture was stirred for 1 hour without heating. Ether
(100 cm3) was added, the ethereal solution was washed
with water, dried with MgSO4, filtered and evaporated to
produce 485 mg (70%) spectroscopically pure
compound having formula 9 in the form of a white solid.
Melting point 172°-174° C. (from hexane). 1H NMR
(CDCl3) d 6.55 (1H); 3.8 (m, 3H); 2.85 (m, 4H); 2.4 (m,
2H); 2.1-1.2 (m, 22H). 13C NMR (CDCl3): d 171.5;
135.9; 130.3; 58.7; 53.9; 39.4; 39.0; 38.2; 37.6; 37.0;
35.3; 33.2; 32.1; 32.0; 31.7; 31.2; 30.5; 28.2; 27.2. IR
(KBr): 3500, 2920, 1650, 1550, 1455, 1100 cm-1. Mass:
M+ at m/e 355 (100%); 266, 91, 73. Exact mass: calcu-




The chloro-substituted compound having formula 2
(605 mg, 200 mmoles) and d,l-lactonitrile (9.2 g) were
mixed under a nitrogen atmosphere, while AgBF4 (600
mg, 3 mmoles) was added with stirring at 50° C. After
30 minutes, ether (110 cm3) was added. The ethereal
solution was washed with water (8 ´ 100 cm3), dried
with MgSO4, filtered and evaporated to yield 440 mg
(62%) of spectroscopically pure compound having for-
mula 10 in the form of a white powder. 1H NMR
(CDCl3) d 7.0 (br, 1H); 4.20 (q, J=13 c, 1H); 3.85 (m,
1H); 2.9 (m, 4H); d 2.1-1.0 (m, 26H with doublet J = 13
Hz at 1.40). 13C NMR (CDCl3): d 174.0; 173.96; 135.9;
130.4; 68.1; 53.4; 39.3; 39.0; 37.6; 37.0; 35.2; 33.1;
32.1; 32.0; 31.6; 31.2; 30.5; 30.4; 28.3; 28.2; 27.3; 21.0:
IR (KBr): 3450, 2930, 1650, 1540, 1455, 1120 cm-1.
Mass: M+ at m/e 355 (100%); 267, 266, 91.79. Exact
mass: calculated for C23H33NO2 355.251; found 355.249.
EXAMPLE VIII
Preparation of N-(4-eq.-adamantylidene
adamanty1)acrylamide (formula 11 )
To a stirred solution of the chloro-substituted com-
pound having formula 2 (3.02 g, 10 mmoles), 100 mg
hydroquinone, and 30 cm3 a rylonitrile in 80 cm3 diox-
ane, AgBF4 (4.4 g) was added in 4 portions at 40° C.
under a nitrogen atmosphere in the course of 2 hours.
After this period a further quantity of 10 cm3 acryloni-
trile was added to the yellow mixture, whereafter the
wh le was stirred at room temperature for 20 hours.
The reaction mixture was filtered to remove precipi-
tated AgCl, diluted with ether (200 cm3), washed with
water, dried with MgSO4, filtered and evaporated to
yield 2.7 g of a yellowish solid. Column chromatogra-
phy over Al2O3 using CH2CL2/benzene (1/1) as the
eluent and re crystallization from MeOH produced 1.81
g (54%) pure compound having formula 11: melting
point 190.5°-192° C. 1H NMR (CDCl3): d 6.20-6.08 and
d 5.6-5.4 (complex ABC systems and -NH absorption,
4H), 3.9 (m, 1H); 2.85 (m, 4H); 2.1-1.3 (m, 22H). 13C-
NMR (CDCl3): d 164.6; 135.9 (s); 131.3 (d); 130.4 (s);
125.6 (t); 54.1; 39.4; 39.3; 38.9; 37.7; 37.0; 35.2; 33.1;
32.1; 32.0; 31.6; 31.2; 30.5; 28.3; 28.2; 27.3. IR (KBr):
3400, 2950, 660, 1630, 1535, 1460, 1220 cm-1. Mass
M+ at m/e 337 (100%); 266 with a meta-stability at
210; 213; 91, 79. Exact mass: calculated for C23H31NO:
337.241. Found: 337.243.
EXAMPLE IX
Preparation of adamantylidene adamantan-4-one
(formula 12)
A mixture of the chloro-substituted compound hav-
ing formula 2 (10.1 g; 33 mmoles) and AgClO4 (12 g)
in 250 cm3 DMSO was heated at 150°-160° C. under a
nitrogen atmosphere for 25 hours. After cooling and
filtration, the product was extracted with n-hexane (4 ´
15 moles). The hexane solution was washed with water,
dried with MgSO4, decolourized with 0.5 g activated
charcoal, filtered and evaporated to produce 8.4 of the
crude compound having formula 12. Chromatography
over a short Al2O3 column, using CH2 l2 as the eluent
produced 7.15 g (76%) of the spectroscopically pure
compound having formula 12 in the form of a white
solid. All spectroscopic data were identical to those of
the authentic sample. 13C NMR (CDCl3): d 215.5;
138.0; 129.2; 51.7; 46.2; 41.4; 39.2; 39.1; 38.1; 38.7;




To a solution of 6.0 g (24 mmoles) AgBF4 in 27 g
ethylcarbamate, a solution of 6.05 g (20 mmoles) of the
chloro-substituted compound having formula 2 in 250
cm3 of dioxane was added at 60° C. with stirring in the
course of 15 minutes. The mixture was refluxed for a
further period of 20 minutes, cooled, and concentrated
at a reduced pressure. Ether (200 cm3) was added, the
etheral solution was washed with water (3 ´ 200 cm3),
dried with MgSO4, filtered and evaporated. 100 cm
3
iso-octane was added and evaporated, and this was
repeated three times to removal residual quantities of
ethylcarbamate. Column chromatography over Al2O3
(10 cm path, dia. 5 cm) using CHCl3 as the eluent pro-
duced 6.54 g pure compound having formula 13 (87%)
in the form of a white solid. Melting point 158°-159° C.
(from EtOH/H2O). 
1H NMR (CDCl3): d 5.0/br, 1H); 4.1
(q, J=8 C, 2H); 3.65 (1H); 2.92 (m, 4H); 2.2-05 (25H)
with triplet J = 8 Hz at 1.27 ppm. 13C NMR (CDCl3): d
155.7; 135.8; 130.6; 60.3 (t); 55.4 (d); 39.4; 38.9; 37.7;
37.0; 35.7; 32.9; 32.1; 32.0; 31.1; 30.5; 28.3; 27.3; 14.4
















1335 cm-1. Mass: M+ at m/e 355 (100%); 267, 91.79.
Exact mass: calculated for C23H33NO2 355.251. Found:
355.248.
EXAMPLE XI
Preparation of 4-eq.-adamantylidene adamantane
isothiocyanate (formula 14)
To a solution of AgBF4 (2.4 g, 12 mmoles) and
freshly distilled benzylthiocyanate in 40 cm3 dioxane, a
solution of the chloro-substituted compound having
formula 2 (2.42 g, 8 mmol) in 40 cm3 dioxane was added
with stirring over a period of 45 minutes. After being
stirred for another hour, the mixture was concentrated at
a reduced pressure. Ether was added, the solution
washed with water, dried with MgSO4, filtered, and
evaporated at a greatly reduced pressure. Column
chromatography over Al2O3, using Ch2Cl2 as the eluent
produced 1.6 g (61 %) spectroscopically pure compound
having formula 14 in the form of a white solid, melting
point 180°-181° C. (from n-heptane). 1H-NMR (CDCl3):
d 3.75 (br, 1H), 3.12 (br, 1H); 2.87 (br, 3H); 2.3-1.2 (m,
22H). 13C-NMR NMR (CDCl3): 137.6; 129.7; 128.8;
62.5; 39.4; 38.7; 37.3; 36.9; 36.8; 33.0; 32.3; 32.2; 31.2;
30.3; 28.2; 27.2: Ir (KBr): 2940, 2200, 1460, 1345, 1085,
765 cm-1. Mass: M+ at m/e 325, 267, 91, 79, 41. Exact
mass: calculated 325.186. Found: 325.185.
EXAMPLE XII
Preparation of 4-eq.-chloroadamantylidene adamantane
(Formula 2)
To a solution of 1 mmol (268 mg) adamantylidene
adamantane having the formula 19 in 20 cm3 CH2Cl2,
1.05 mmoles (140 mg) N-chlorosuccinimide was added.
The reaction mixture was stirred at room temperature for
1 hour, diluted with CH2Cl2, and washed twice with
water. The organic layer was dried with MgSO4 and
evaporated. The yield of 4-eq.-chloroadaman-
tylideneadamantane was 300 mg (98%), melting point:
142°-143° C. (literature: 144°-145° C.). 1H NMR
(CDCl3): d 4.15 (br s, 1H); 3.05 (br s 1H); 2.8 (br s, 3H);
2.6-1.15 (br m, 22H) ppm. When 0.1 mmol hydroqui-
none was added to the solution, exactly the same reac-
tion occurred, and the product could be isolated in




To a solution of 3 mmols (804 mg) adaman-
tylideneadamantane in 40 cm3 CH2Cl2, 6.6 mmols (1.175
g) N-bromosuccinimide was added. The reaction mixture
was refluxed and stirred for 12 hours. The reaction
mixture was diluted with CH2Cl2 and washed twice with
water and a saturated Na2S3O3-Solution. The organic
layer was dried with MgSO4 and evaporated. The yield
of 4-eq.-bromoadamantylideneadamantane having
formula 20 was 1.05 g (97% ). An analytically pure sam-
ple could be obtained by crystallization from acetone and
sublimation (115° C./0.002 mm); melting point 130.5-
131.5° C. 1H NMR (CDCl3); d 4.4 (br s, 1H); 3.05 (br s,
1H); 2.8 (br s, 3H); 2.6-1.2 (br m, 22H); 13C NMR
(CDCl3); d 136.9 (s); 131.0 (s); 63.8 (d) and 12 signals
between 39.9 and 27.6. Analysis, calculated: 69.16 C;
7.84 H; 23.01 Br; found: 69.21 C; 7.82 H; 22.99 Br.





To a solution of 200 mg (0.82 mmol) of bicyclo[3,-
3,1]nonylidene-bicyclo[3,3,1]nonane (formula 17) in 20
cm3 CH2Cl2, 115 mg (0.86 mmol) N-chlorosuccinimide
was added. The reaction mixture was refluxed and
stirred for 1 hour, and CH2Cl2 was added to dilute the
reaction mixture. The organic layer was washed twice
with water, dried with MgSO4 and evaporated. The
yield of 4-eq.-chlorobicyclo[3,3,1]nonylidene-bicy-
clo[3,3,1]nonane was 190 mg. Purification was effected
via chromatography (hexane, Al2O3) and sublimation
(45° C./0.01 mm), melting point 50.53° C., 1H NMR
(CDCl3) d 4.4-3.9 (m, 1H); 3.1 (br s, 1H): 2.85 (br s,
3H); 2.5-1.2 (br, 22H); 13C NMR (CDCl3) d 136.8 (s);
129.7 (s); 66.0 (d) and lines between 39.7 and 21.7;






The bromo-substituted compound having formula 16
(220 mg, 0.58 mmol) was dissolved in dry dioxane (10
cm3) and 2-chloroethanol (5 cm3) was added. The mix-
ture was refluxed for 18 hours, cooled, and concentrated
at a reduced pressure. Water (50 cm3) was added and
th  product was twice extracted with n-hexane, with the
combined extracts being washed with brine. The hexane
solution was dried with MgSO4, filtered and
concentrated at a reduced pressure. Column-
chromatography over Al2O3 (act. II/III), using hexane as
the eluent, produced 180 mg (0.52 mmol, 89.7%) of
pure compound having formula 23 in the form of a
colourless oil. IR (neat) 2950 (s), 1455 (m), 1100 (s)
and 785 cm-1 (s) 1H-NMR (CCl4, TMS): d 3.6 (double
triplet, 4H), 3.25 (m, 1H), 2.85 (m, 5H), d 2.4-1.1 (m,
22H), 13C-NMR (CBCl3): d 135.8; 130.8; 82.6 (d); 67.9
(t); 43.2 (t); 39.7; 39.6; 39.5; 39.1; 37.1; 36.8; 35.7;
33.0; 32.4; 32.1; 31.8; 31.0; 30.1; 28.4 and 27.6. Mass:
M+ at m/e 346 (100%). Exact mass: calculated for





The bromo-substituted compound having formula 16
(200 mg, 0.58 mmol) was dissolved in dry dioxane (10
cm3) and 3-bromopropanol-1 (5 cm3) was added. The
mixture was subsequently refluxed for 18 hours, and
then concentrated at a reduced pressure. Water was
added, and the product was extracted twice with n-hex-
ane. The combined organic layers were washed with
brine, dried with MgSO4, filtered and evaporated sub-
stantially to dryness. Chromatography (see Example
XV, the compound having formula 19) produced 195
mg (0.57 mmol, 85% ) of the compound having formula
20 in the form of a colourless oil. IR (neat): 2900 (s),
1450 (m) and 1100 cm-1 (s). 1H-NMR (CCl4, TMS): d
3.50 (t, J=6 Hz, 4H); 3.2 (m, 1H), 2.9 (m, 4H); 2.4-1.1
















68.2 (t); 64.6 (t); 39.7; 39.5; 39.4; 39.1; 37.2; 36.8;
35.7; 33.3; 33.0; 32.7; 32.3; 32.0; 31.7; 31.11; 31.08;
30.9; 30.4; 28.4; 27.6. Mass: M+ at m/e 404/406 (1-1;






The bromo-substituted compound having formula 16
(200 mg, 0.58 mmol) was dissolbed in dry DMF (1'
cm3), and L-menthol (1 g, 5.8 mmol) was added. The
mixture was refluxed for 18 hours and concentrated at a
reduced pressure. Chromatography (following the pro-
cedure of Example XV, the compound having formula
19) produced the compound having formula 21 in the
form of a colourless oil, yield 240 mg (98%). IR (neat):
2900 (s), 1450 (m), 1090 (s), 730 (s) cm-1. 1H-NMR
(CDCl3, TMS): d 3.6-2.8 (m, peaks at 3,5 and 3.0, 6H),
2.6-07 (m, 40H; peaks at d 1.9, 1.0. 0.9 and 0.75). 13C-
NMR (CDl3): d 135.22; 135.13; 131.86; 131.70; 80.1;
79.3; 78.2; 76.9; 49.1; 48.9; 42.0; 41.7 (all pairs of both
diastereomeric isomers) and 26 peaks between d 40 and
16. Mass: M+ peak at m/e 422.267 (100%), 283, 135.






The bromo-substituted compound having formula 16
(200 mg, 0.58 mmol) was dissolved in dry DMF (10
cm3). Testosterone (1 g, 3.5 mmols) was added and the
mixture was refluxed for 18 hours. Evaporation of the
solvent, and columnchromatography (Al2O3), activity
II/III, using CH2Cl2 as the eluent, produced 240 mg of
crude product in the form of a yellow oil. The pure
compound having formula 22 was obtained after plate
chromatography (Al2O3/CH2Cl2) as a white solid. The
yield was 100 mg (30%). [a]478
rI = +44.6 (c= 1.3;
CH2Cl2). IR (KBr pellet): 2900 (s), 1680 (s), 1460 (m),
1090 (m) cm-1. 1H-NMR (CDCl3, TMS): d 5.75 (br,
1H); 3.6-3.1 (m, 2H); 3.1-2.6 (m, 4H); 2.6-05 (m, 47H)
with peaks at d 1.8, 1.25, 1.2 and 0.85. 13C-NMR
(CDCl3): d 199.2; 171.1 (s); 135.0 (s); 131.2 (s); 123.6
(d); 85.4; 85.2; 80.4; 80.3; 53.9; 50.4; 42.6 and 27 peaks
between d 40 and 11.5. Mass: M+ peak at m/e 554; 267






The bromo-substituted compound having formula 16
(200 mg; 0.58 mmol) was dissolved in isopropanol (10
cm3) and the solution was refluxed for 18 hours and
subsequently evaporated to leave the compound having
formula 23 in the form of a colourless oil (0.55 mmol,
95%). IR (neat): 2900 (s), 1450 (m), 1080 (s) cm-1. 1H-
NMR (CCl4, TMS): d3.6 (septet, J=7C, 1H), 3.25 (m,
1H); 2.9 (m, 4H) and 2.5-1.0 (m, 28H with sharp
doublet at d1.15, J=6C). 13C-NMR (CDCl3): d135.2;
131.4; 78.7; 67.4; 39.7; 39.6; 39.5; 39.4; 39.2; 37.2;
37.1; 36.1; 33.0; 32.5; 32.3; 32.1; 31.2; 31.0; 28.4; 27.2;
22.8; 22.6. Mass: M+ peak at m/e 326 (100%); 268,






The bromo-substituted compound having formula 16
(200 mg, 0.58 mmol), dioxane (10 cm3) and
propanediol-1.3 (5 cm3) were mixed, and refluxed for
18 hours. Dioxane was evaporated, and the residue
dissolved in CH2Cl2 (50 cm
3). The solution was treated
with H2O (3 ´  50 cm
3), dried with MgSO4, filtered, and
vaporated to produce 180 mg (91%) spectroscopically
pure compound having formula 24 in the form of a
colourless oil. Analytically pure material was obtained
after "Kugelrohr"to distillation (250° C., 0.002 mm Hg).
Analysis: calculated for C23H34O2: 80.63% C 10.02% H.
Found 80.52% C 9.95% H. IR (neat): 3400 (s), 2900 (s),
1450 (s), 1100 (br) cm-1. 1H-NMR (CCl4, TMS): d3.6 (t,
J=7C, 2H), 3.5 (t, J=7C, 2H); 3.2 (br, 1H); 2.9 (br, 4H);
2.3-1.0 (m, 25H). 13C-NMR (CDCl3): d135.4; 130.5;
82.1 (d); 66.6 (t); 61.8 (t); 39.2; 38.8; 36.9; 36.5; 35.2;
32.8; 32.0; 31.7; 31.3; 30.8; 30.6; 28.1; 27.3. Mass: M+




The bromo-substituted compound having formula 16
(347 mg, 1 mmol) was dissolved in dioxane (15 cm3)
and H2O (5 cm
3) was added. After refluxing for 0.5
hour, the solvents were removed by evaporation, and
CH2Cl2 (100 cm
3) was added. After treating this solu-
tion with H2O (2 ´  100 cm3) MgSO4 was added, the
solution was filtered and evaporated to produce the
c mpound having formula 3 (280 mg, 99% ) in the form





A solution of the bromo-substituted compound having
formula 16 (200 mg, 0.58 mmol) in acetic acid (10 cm3)
was refluxed for 36 hours. Evaporation of the solvent
and fast chromatography over a short column of Al2O3
(activity II/III), using n-hexane as the first eluent and
then CH2Cl2, produced the compound having formula
25 (140 mg, 74%) in the form or a colourless il, which
after standing for 1 day solidified. IR (neat): 2950 (s),
1715 (s), 1220 (s) cm-1. 1H-NMR (CDCl3, TMS): d4.7
(br, 1H); 3.1-2.6 (br, 4H); 2.2-1.2 (m, 25H; with a peak
at 2.05 for -CH3). 
13 C-NMR (CDCl3): d170.4; 136.7;
129.8; 77.1; 39.6; 39.5; 39.4; 39.0; 37.1; 36.9; 36.7;
35.6; 33.3; 32.4; 32.2; 31.6; 31.3; 30.6; 28.4; 28.3; 27.4;
21.4. Mass: M+ peak at m/e 326. Exact mass: calculated




A mixture of the bromo-substituted compound having
formula 16 (200 mg, 0.58 mmol), dioxane (10 cm3) and
















duced pressure, and dissolved in ether (50 cm3). The
ethereal solution was washed with H2O (2´ 50 cm
3) and
brine (1 ´ 50 cm3), dried with MgSO4, filtered, and
evaporated to produce 100 mg (49%) of pure compo nd
having formula 26 in the form of a white solid. Melting
point: 172°-174° C. (from hexane). IR (KBr pellet): 3300
(m, br), 2900 (s), 1640 (s), 1540 (m), 1450 (m) cm-1. 1H-
NMR, 13C-NMR and mass identical to the reaction with
Ag30.
EXAMPLE XXIV
Preparation of 4 eq.-iodo-adamantylidene admantane
(formula 27)
The bromo-substituted compound having formula 16
(347 mg, 1 mmol) was added to a solution of NaJ (4.5 g)
in acetone (25 cm3), and the whole was then refluxed for
20 hours. The solvent was evaporated, ether (50 cm3)
was added, whereafter the solution was treated with
water (2 ´ 50 cm3), concentrated Na2S2O3 (1 ´  50 cm
3)
and water (1 ´ 50 cm3). The ethereal solution was dried
with MgSO4, filtered and evaporated to produce 340 mg
(86% ) of pure compound having formula 27 in the form
of a white solid. IR (KBr pellet): 2950 (s), 1450 (s), 1145
(m), 965 (m), 750 (m) cm-1. 1H-NMR (CDCl3, TMS):
d3.2-2.7 (m, 4H); 2.7-1.0 (m, 22H). 13C-NMR (CDCl3):
d136.6; 131.2; 47.3; 41.1; 40.1; 39.5; 39.3; 37.5; 36.9;
34.3; 32.6; 32.3; 32.1; 30.7; 28.2; 27.9. Mass: M+ peak
at m/e 394; 267 (100%). Exact mass: calculated for




The bromo-substituted compound having formula 16
(1,5 mmol) was dissolved together with a pinch (ap-
proximately 12 mg) of methylene blue in 200 cm3 of
distilled CH2Cl2. This solution was transferred to a
reactor which was made mainly of glass.
In the reaction vessel, a porous P-4 glass filter is
provided. Placed on reaction vessel is a spherical cooler
with a superjacent glass tube, approximately 1 m long.
Placed on top of the reaction vessel is further a supply
vessel for the solvent (in this case CH2Cl2).
Before the solution was transferred to the reaction
vessel, oxygen (O2) was passed through the reaction
vessel. When the solution was added to the reaction
vessel, this oxygen stream became visible from the rising
in the solution of finely divided bubbles.
The solution present in the reaction vessel was irradi-
ated with the sodium vapour lamp and the reflector,
placed close to the reaction vessel, for 6 hours, with the
liquid level being replenished from time to time with
CH2Cl2 from the supply vessel. During the reaction the
temperature of the solution rose to approximately 40° C.
The course of the reaction was followed by means of
thin-layer chromatography (aluminum oxide/CH2Cl2 or
n-hexane).
After completion of the reaction, the solution was
poured out and decolorized with activated charcoal. The
reaction product was purified by column chroma-
tography to product 4-eq.-bromo-2,2'-epidioxy-2,2'-
adamantyl adamantane.
EXAMPLE XXVI
Preparation of 4-eq.-[12-oxy-dodecanoic acid methyl
ester]-adamantylidene adamantane (formula 32)
To a solution of 10 g 12-hydroxydodecanoic acid
methyl ester having the formula 35 and 7 g AgClO4 in
200 cm3 1.4-dioxane, a solution of 5 g 4-eq.-
chloroadamantylidene adamantane (formula 2) in 100
cm3 dry 1.4-dioxane was added. The reaction mixture
was stirred at room temperature for 40 hours, and subse-
quently poured into 500 cm3 water and extracted with
ether (3 ´ 200 cm3). The combined organic layers were
washed with water (7 ´ 150 cm3), dried by means of
MgSO4, and evaporated, to produce 14.5 g crude mix-
ture. The excess of compound having formula 35 was
removed by means of column chromatography (Al2O3
act. II/III; CH2Cl2). Three crystallizations from metha-
nol produced 2.98 g of the compound having formula
32. Gas chromatographic analysis showed, however,
that approximately 15% dodecane lactone (formula 36)
was present.
A suitable way of purifying the compound having
formula 32 comprised the following procedure: the
crude mixture was, after column chromatography (see
supra), dissolved in 250 cm3 methanol together with 0.5
g p-toluenesulphonic acid, and refluxed for 14 hours.
After cooling the solvent was evaporated and the reac-
tion mixture chromatographed over an Al2O3 (II, II),
CH2Cl2 column to produce a mixture of the compound
having formula 32 and 4-eq.-methoxyadamantylidene
adamantane (formula 5). The latter compound was re-
moved by hydrolysis of the compound having formula
32 with 2 g LiOH in ethanol, water (10:10 cm3) at room
temperature for 12 hours, followed by column chroma-
tography (Al2O3 II, III; CH2Cl2) which produced the 4-
eq.-methoxy compound. The pure compound having
formula 32 was isolated by Soxhlet extraction of the
column chromatography material with 300 cm3 metha-
nol containing 0.5 g p-toluenesulphonic acid, followed
by column chromatography (Al2O3 II, III, CH2Cl2). An
analytically pure sample of the compound having for-
mula 32 was obtained by crystallization from methanol:
melting point 44°-48° C., IR(Nujol): 2900, 1740, 1470,
1390, 1100 cm-1; 1H-NMR (CDCl3) d3.68 (s. 3H); 3.56-
31. (br. 3H); 3.1-2.7 (br. 4H); 2.5-2.1 (br. 2H); 2.1-1.5
(br. adamantane); 1.5-1.15 (br. CH2 chain). 
13C-NMR
(CDCl3): d174.2; 135.3; 131.2; 81.7; 67.4; 51.3 and 21
lines between 39.5-24.8. Mass spectrum m/e calc.: 496,
392; found 496,393. Analysis: calc.: 79.79 C; 10.55 H;
found: 79.87 C; 10.47 H.
EXAMPLE XXVII




A solution of 240 mg of the compound having for-
mula 32 and 15 mg methylene blue in 200 cm3 CH2Cl2
was irradiated with a high-pressure mercury lamp, while
a slow stream of oxygen was passed through the
solution. The UV light was filtered with a K2Cr2O7
solution. The reaction was followed by gas chromato-
graphic analysis. A reaction period of 7 hours was re-
quired for complete conversion of the olefin in the 1,2-
dioxetane having formula 33. The dichloromethane was
evaporated from the reaction mixture, which was then
















The yield of compound having formula 33 in the form of
a colourless oil was 240 mg (94% ): IR neat: 2900, 1715,
1460 and 1100 cm-1; 1H NMR (CDCl3): d3.60 (S 3H);
3.6-3.2 (br.m., 3H); 2.8-2.4 (br.m., 4H); 2.4-1.0 (br. m.,
42H); 13C NMR (CDCl3): d174.1 (s); 96.4 (s); 960 (s);
95.6 (s); 95.5 (s); 76.0 (d); 67.9 (d); 67.7; 51.2 (q) and 24
lines between 37.0 and 24.8 ppm.
EXAMPLE XXVIII




To a solution of 240 mg of the compound having
formula 33 in 15 cm3 ethanol, a solution of 250 mg LiOH
in 3 cm3 water was added. The reaction mixture was
stirred at room temperature for 12 hours. After
acidification (pH=4) with 0.1N H2SO4, the reaction
mixture was extracted with CH2Cl2 (2 ´  30 cm
3). The
organic layer was dried by means of MgSO4, and con-
centrated. The yield of compound having formula 34 in
the form of a colourless oil was 216 mg (92% ): IR neat:
2900, 2500-3500, 1700, 1460, 1260, 1220 cm-1; 1H NMR
(CDCl3) d10.2-9.9 (s, 1H); 3.7-3.2 (br. m., 3H); 2.9-2.4
(br. m., 4H); (br. m., 42H); 13C NMR (CDCl3): d179.7
(s); 95.8 (s); 95.4 (s); 95.3 (s); 75.9 (d); 75.7 (d); 67.8




methyl ester (formula 38)
To a stirred solution of 8 g of the compound having
formula 37 and 3.5 g 4-eq.-chloroadamantylidene ada-
mantane (formula 2) in 250 cm3 p-dioxane under a nitro-
gen atmosphere, 4.4 g AgBF4 was added. The reaction
mixture was stirred at room temperature for 15 hours and
diluted with ether. The organic layer was washed with
water (six times), dried by means of MgSO4, and
concentrated. The crude product was thoroughly washed
with methanol to remove the starting materials. The yield
of compound having formula 38 was 4.5 g (95%). An
analytically pure sample was obtained by crystallization
from CH2Cl2/iso-propyl alcohol; melting point: 162.5°-
164° C.; IR (Nujol): 1740, 1289, 1095 cm-1; 1H NMR
(CDCl3): d3.57 (s, 3H); 3.45-3.2 (br.m., 2H); 3.0-2.6
(br.m. 4H); 2.4-04 (br.m., 53H); 0.84 (s, 3H), 0.55 (s,
3H); 13C NMR (CHCl3): d174.0 (s); 134.9 (s); 131.2 (s);
78.2 (d), 75.2 (d), 56.1 (d), 55.7 (d); 50.9 (q) and 29 lines
between 42.3 and 11.7 ppm; analysis C45H68O3: calc.:
82.26% C; 10.43% H; found: 82.06% C; 10.44% H.
EXAMPLE XXX
Preparation of 3-O-(4-eq.-2,2'-epidioxy-2,2'-adamantyl
adamantane)lithocholic acid methyl ester (formula 39)
A solution of 2.5 g of the compund having formula 38
and 50 mg methylene blue in approximately 350 cm3
CH2Cl2 was irradiated with a high-pressure mercury
lamp, while a slow stream of oxygen was passed
through the solution. The UV light was filtered by
means of a K2CR2O7 solution. Complete conversion
required a reaction period of 20 hours The solvent was
evaporated from the reaction mixture, and the residue
was purified over an Al2O3 (act. II/III) column with
CH2Cl2. The yield of compound having formula 39, in
the form of white crystals, was 2.0 g (76%). An analyti-
cally pure sample was obtained by crystallization from
iso-propylalcohol; melting point: 119°-121° C.; IR
(nujol) 1740; 1160; 1100 cm-1; 1H NMR (CDCl3) d3.7-
3.4 (br.m., 1H); 3.54 (s, 3H); 3.4-3.0 (br.m. 1H); 2.7-2.3
(br .m. 4H); 2.3-0.4 (br .m. 53H); 0.77 (s, 3H); 13C NMR
(CDCl3): d174.0 (s), 96.0 (s), 95.5 (s); 95.2 (s); 94.9 (s);
75.7 (d); 75.3 (d); 72.6 (d), 56.0 (d), 50.9 (q) and 28
lines between 42.3 and 11.6 ppm.; analysis C45H68O5




lithocholic acid (formula 31)
To a solution of 200 mg of the compound having
formula 39 in 25 cm3 ethanol, 350 mg LiOH in 5 cm3
water was added. The reaction mixture was stirred at
room temperature for 12 hours. After acidification
(pH=4) with 0.1N H2SO4, the reaction mixture was
extracted with CH2 l2. The organic layer was dried by
m ns of MgSO4 and concentrated. The yield of com-
pound having formula 31 in the form of white crystals
was 192 mg (98%): melting point: 138°-140° C.; IR
(Nujol): 3700-2700; 1705, 1090 cm-1; 1H NMR (CDCl3)
d3.8-3.3 (br.m, 1H); 3.6-3.0 (br.m. 1H); 2.8-2.3 (br.m.,
4H); 2.5-94 (br.m., 53H); 0.8 (s, 3H); 0.55 (s., 3H) and
10.1-10.7 (br.s., 1H); 13C NMR (CDCl3): d180.3 (s);
96.4 (s); 59.9 (s); 95.7 (s); 95.5 (5); 75.7 (d); 75.4 (d);





Under a dry nitrogen atmosphere and with exclusion
of light, a mixture of 6.05 g 4-eq.-chloroadamantylidene
adamantane (formula 2), 200 cm3 dry toluene, 20 mg
hydroquinone and 5.2 g silver maleimide (formula 41)
(from silver nitrate and maleimide) was boiled for 27
hours. After evaporation and addition of 100 cm3 ether,
a mixture of solids was obtained. Extraction by means of
a Soxhlet apparatus, using ether as the solvent for 18
hours, and evaporation of the extract produced 6.0 g
yellowish solid. Column chromatography over Al2O3
(act. II/III) with benzene as the eluent, evaporation and
water with 20 cm3 ether gave 2.7 g (37%) pure malei-
mide; melting point: 199°-202° C. 1H-NMR (CDCl3,
TMS): d6.52 (s, 2H); 3.9 (m, 1H); 3.5 (m, 2H); 2.9 (m,
4H); 2.7-1.0 (m, 20H). 13C NMR (CDCl3): d171.9;
135.9; 133.8; 130.9; 61.5; 39.4; 39.0; 37.1; 34.0; 32.3;
32.1; 31.9; 31.0; 30.2; 28.3; 26.9. IR (KBr): 2900 (s),
1700 (s), 1340 (m) cm-1. Mass: M+ peak at 363. Exact





The olefin having formula 40 (500 mg) was subjected
to photooxygenation in the manner specified before,
except that the reaction period was 18 hours. Column
chromatography over Al2O3 (act. III), using benzene as
the eluent gave after a fIrst fast travelling impurity the
isomer having the formula 42a (75 mg) in the pure form
















the pure form, and both as white solids (together 25%
yield).
Formula 42a:
1H-NMR (CDCl3, TSM): d6.5 (s, 2H), 4.2 (m. 1H), 3.4
(m, 1H), 2.9-2.5 (m, 4H), 2.4-1.0 (m, 21H). IR (KBr):
2950 (s), 1700 (s), 1365 (m), 1345 (m), 685 (m) cm-1.
13C-NMR (CDCl3): d171.7; 133.9; 95.8; 55.8; 37.1; 35.2;
34.4; 33.9; 33.0; 32.2; 31.9; 31.3; 30.9; 29.5; 27.2; 26.5;
26.3; 24.9.
Formula 42b:
1H-NMR (CDCl3, TMS): d6.55 (s, 2H), 4.15 (m, 1H),
3.4 (m, 1H), 2.9-2.4 (m, 4H), 2.4-1.0 (m, 21H).IR (KBr):
2900 (s), 1700 (s); 1375 (m), 690 (m) cm-1. 13C NMR
(CDCl3): d171.7; 133.9; 95.9; 55.3; 37.1; 34.5; 34.1;





adamantane (formula 29) ("anti-isomer")
200 mg of the compound having formula 43, 284 mg
pro-analysis iodo acetic acid and 150 mg pro-analysis
pyridine were together dissolved in 30 cm3 distilled
CH2Cl2. After the solution had been cooled to 0° C.,
brought under a nitrogen atmosphere, and sealed from
light, a solution of 330 mg DCC (dicyclohexylcarbodi-
imide) in 2 cm3 CH2Cl2 was injected by means of a glass
syringe with stirring. Without further cooling, the mix-
ture was stirred for three days. After evaporation, 50 cm3
benzene was added, the solution was filtered and the
residue washed with benzene. The combined benzene
solutions were washed with 5% Na2S2O3 solution (2 ´ 50
cm3) and H2O (1 ´  50 cm
3), dried by means of MgSO4,
filtered, and evaporated. The yellow solid residue was
dissolved in pro-analysis acetone and the solution was
partially decolorized by means of decolorizing charcoal.
After fIltration, the solution was thickened to about 25
cm3 volume, subsequently a little water was added, the
solution was filtered and then allowed to stand for 18
hours at -40° C. for crystallization. Filtration and drying
produced 140 mg pure product (42%); melting point
137.2°-137.9° C. 1H-NMR (CDCl3, TMS): d5.15 (br,
1H); 3.75 (s, 2H): 3.1-2.4 (m, 4H); 2.4-1.1 (m, 22H). IR
(KBr): 2900 (s), 1720 (s) and 1265 (s) cm-1. 13C-NMR
(CDCl3): d167.9; 95.6; 95.2; 74.1; 36.9; 35.8; 34.7; 34.3;
32.9; 32.0; 31.8; 31.5; 31.4; 30.9; 30.5; 30.1; 26.5; 26.3;
25.3; -5.1.
The reaction to form 4-eq.-(a-iodoacetoxy)-2,2'-epi-
dioxy-2,2'-adamantyl adamantane (formula 29) can also
be carried out on a mixture of syn and anti hydrox-
ydiadamantyl-1,2-dioxetane. There is then formed a
mixture of syn and anti a-iodoacetoxy compounds in the
same yield. The I.R.- and the 1H-NMR-spectra are
identical to those of the pure anti-isomer. 13C-
NMR(CDCl3): d167.9; 167.5; 95.5; 95.7; 95.2; 74.3; 74.1
and 27 peaks between 39.1 and 25; -41.9 and -5.1.
The syn- and anti-4-eq.-hydroxy-1,2-dioxetanes
needed for the above synthesis, can be prepared from 4-
eq.-hydroxyadamantylidene adamantane via the photo-
oxygenation method in a quantitative yield (after
purification by column chromatography over Al2O3 (act.
II/III) using ether as the eluent. The separation of syn-
and anti-isomers is effected by means of plate chro-
matography with Al2O3 and CH2Cl2 as the eluent.
We claim:
1. A process for preparing a 4-equatorially halogen-
substituted polycyclo-alkylidene polycyclo-alkane,
comprising halogenating, in a solvent, the correspond-
ing nonsubstituted polycyclo-alkylidene polycyclo-
alkane compound with a halogenating agent of the
class consisting of N-halosuccinimide, tert.-butyl-
hypohalite and sodium hypohalite/CH3COOH.
2. The process of claim 1 wherein said halogen is
chlorine and, corresponding, said halogen-substituted
polycycloalkylidene polycyclo-alkane is a chlorine-
substituted polycycloalkylidene polycyclo-alkane.
3. The process of claim 2, further comprising the step
of substituting, in a solvent and in the presence of a
silver salt, said chlorine using, as substituting agent, a
nucleophile.
4. The process of claim 3, wherein said silver salt is
selected from the group consisting of AgBF4 or Ag-
ClO4.
5. The process of claim 1, wherein said halogen is
bromine.
6. The process of claim 5, further comprising the
step of substituting, in a solvent, in the absence of a
silver salt, said bromine using, as substituting agent, a
nucleophile, and wherein said solvent comprises said
nucleophile.
7. The process of claim 6, wherein said solvent fur-
ther comprises a co-solvent selected from the group
consisting of dimethylformamide and dioxane.
8. The process of claim 5 wherein the product of said
halogenation is subjected to a halogen-exchange reac-
tion.
9. The process of claim 8, wherein said halogen-
exchange reaction is carried out with NaI/acetone mix-
ture to form the corresponding iodo-substituted com-
pound.
10. The process of claim 1 wherein said polycycloal-
kylidene polycyclo-alkane is adamantylidene adaman-
tane.
11. A process for preparing a 4-equatorially substi-
tuted epidioxy polycyclo-alkylidene polycyclo alkane,
comprising subjecting a compound selected from the
group consisting of:
A. 4-equatorially-halogen-substituted polycycloalk-
ylidene polycyclo-alkane formed by halogenating,
in a solvent, the corresponding non-substituted
polycyclo-alkylidene polycyclo-alkanes with a
halogenating agent of the class consisting of N-
halosuccinimide, tert.-butyl-hypohalite, and so-
dium hypohalite/CH3 OOH, and
B. The compounds resulting from substituting said
halogen in said 4-equatorially-halogen-substituted
polycyclo-alkylidene polycyclo-alkanes with a
nucleophile,
to a photo-oxygenation reaction.
12. The process of claim 11, wherein said non-sub-
stituted polycyclo-alkylidene polycyclo-alkane is ada-




13. The process of claim 12, wherein a CH2Cl2 solu-
tion of methyleneblue and 4-eq.-substituted adamanty-
lidene adamantane is subjected to a photo-oxygenation
reaction in a reaction vessel through which oxygen is
passed, and with irradiation for 4-7 hours with a sodi-
um lamp, followed by decolorizing the reaction soluti-
on with activated charcoal, purifying said product with
column chromatography, and recovering said product.

















A and B are alkylene radicals, optionally connected
to each other through an alkylene radical; and
R1 is a substituent, provided that RI is not chloro,
hydroxy, oxo, D or a group having the formula
when said compound is 4-eq.-R1-2,2'-admantylidene
adamantane.
15. The compound of claim 14, wherein said alkylene
radical A contains 2 to 5 carbon atoms, said alkylene
radical B contains 2 to 5 carbon atoms, and said con-
necting alkylene radical contains 1 to 4 carbon atoms.
16. The compound of claim 14, wherein said com-
pound is 4-eq.-R1-2,2'-admantylidene adamantane, pro-
vided that R1 is not chloro, hydroxy, oxo, D or a radical
having the formula
17. The compound of claim 14, wherein R1 is selected
from the group consisting of
chloro, bromo, iodo,
hydroxy,
substituted or unsubstituted alkoxy, cycloalkoxy,
acyloxy, and
amino, acylamino, isothiocyanato, and isocyanato,
provided that if said compound is 4-eq.-R1-2,2'-
adamantylidene adamantane, R1 cannot be chloro,
hydroxy, oxo, D, or a group having the formula
18. A compound having the formula
wherein
A and B are alkylene radicals, optionally connected to
each other through an alkylene radical; and
R1 is selected from the group consisting of an acyloxy
group comprising a protein radical, a cycloalkoxy
comprising a steroid radical attached through an
oxygen, an acyloxy comprising a fatty acid
radical attached through an oxygen.
19. The compound of claim 18, wherein R1 is an
acyloxy group, comprising a protein radical.
20. The compound of claim 19, wherein said protein
radical is a radical of bovine serum albumin.
21. The compound of claim 18, wherein R1, as cy-
cloalkoxy, is a steroid radical attached through an
oxyg n atom.
22. The compound of claim 21 wherein said steroid
radical is selected from the group consisting of testos-
terone and lithocholic acid radicals.
23. The compound of claim 18, wherein R1, as
acyloxy, is a fatty acid radical attached through an
oxygen atom.
24. The compound of claim 23, where said fatty acid
radical is a radical of arachidic acid.
25. A chemiluminescent label comprising a com-
pound having the formula
wherein
A and B represent alkylene radicals, optionally con-
nected to each other through an alkylene radical,
and
R2 is a substitutent,
provided that said substituent is not chloro or hydroxy
when said chemiluminescent compound is 4-eq.-R2-
2,2'-epidioxy-2,2'-adamantyl adamantane.
26. The chemiluminescent label of claim 25, wherein
said optionally connected alkylene radicals A and B
contain 2 to 5 carbon atoms, and
said connecting alkylene radical contains 1 to 4 car-
bon atoms.
27. The chemiluminescent label of claim 25, wherein
said compound is 4-eq.-R2-2,2'-epidioxy-2,2'-adamantyl
admantane, provided that R2 is not chloro or hydroxy.
28. The chemiluminescent label of claim 25, wherein
R2 is selected from the group consisting of
chloro, bromo, iodo,
hydroxy,
substituted or unsubstituted alkoxy, cycloalkoxy, or
acyloxy,
amino, acylamino, isothiocyanato and isocyanato,
provided that R2 is not chloro or hydroxy when said
compound is 4-eq.-R2-2,2'-epidioxy-2,2'-adamantyl
adamantane.
29. The chemiluminescent label of claim 28, wherein
R2 is an acyloxy group comprising a protein radical.
30. The chemiluminescent label of claim 29, wherein
said protein radical is a radical of bovine serum albumin.
31. The chemiluminescent label of claim 28, wherein
R2, as cycloalkoxy, is a steroid radical attached through
an oxygen atom.
32. The chemiluminescent label of claim 31, wherein
said steroid radical is selected from the group consisting
of testosterone and lithocholic acid radicals.
33. The chemiluminescent label of claim 28, wherein
R2, as acyloxy, is a fatty acid radical attached through an
oxygen atom.
34. The chemiluminescent label of claim 33 wherein
said fatty acid radical is an arachidic acid radical.
*   *   *   *   *
